As a CD40 ligand antagonist, dazodalibep blocks immune cell communication, potentially serving as the first drug to target the autoimmune disease’s cause.
Bristol Myers Squibb unveiled promising CAR T cell therapy data for severe autoimmune diseases from their Phase 1 clinical trial, offering hope for remission.
A changing dance of transcription factors modulates T regulatory cell gene expression in different immune contexts with implications for cancer and autoimmune diseases.
Once symptoms show up, it’s too late to cure many autoimmune diseases. Researchers are investigating ways to prevent the conditions from starting at all.